Fig. 3
From: Elucidating the role of EPPK1 in lung adenocarcinoma development
Targeting EPPK1 with CRISPR-Cas9 in A549 cells. A EPPK1 protein expression in lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), large cell neuroendocrine carcinoma (LCNEC), and non-small cell lung cancer (NSCLC). B Western blotting results show that EPPK1 was knocked out in A549. The results confirmed MET due to the upregulation of E-cadherin and downregulation of Vimentin after silencing EPPK1. Further, we confirmed that oncogenes were upregulated, and tumor suppressor genes were downregulated after silencing EPPK1. C Cell proliferation assays reveal that cell growth inhibition was induced after silencing EPPK1 in A549 (mean difference with CI = 2716.851 [187.670–5246.032], P = 0.037). CI: confidence interval. D Representative image of invasion assays for wild type and EPPK1 KO cells in A549 (20x). E Inhibition of cell invasion after silencing EPPK1 in A549 (mean difference with CI = 2.110 [1.817–2.402], P < 0.001). Dot plot with mean and standard error per group by day. CI: confidence interval